Limula raises CHF 6.2 million in oversubscribed Seed round to develop automated Cell and Gene Therapy manufacturing platform – Limula
Summary
The trio witnessed that outdated manufacturing methods were a speed bump to the adoption of Cell and Gene Therapy products like chimeric antigen receptor (CAR) T-cells. As a result, these treatments are inaccessible for a majority of eligible patients.To combat this, Limula developed a modular solution for on-demand and at-scale manufacturing of cell therapies in a single device. By combining the functionalities of a bioreactor and a centrifuge into one single closed vessel, Limulas proprietary solution can handle a wide range of volumes and cell numbers, removing transfer steps and therefore limiting stress, losses, and potential contamination. These two aspects are keys unlocking the full potential of Cell and Gene Therapy, making them accessible to the many, not just the few.Limulas founders built a high performing multidisciplinary team, most recently joined by domain experts Olivier Waridel, former CEO of Cytiva-owned Biosafe, Caroline Boudousqui\xe9, former Head of Process Development at the Center for experimental therapeutics (CTE) of the University Hospital in Lausanne, and Maria Elena Grisostolo, former VP Operations at Lunaphore.After completing an initial proof of concept, the company launched a program to provide selected industry and academic partners access to the innovative platform ahead of its commercial launch. Both industrial and academic players are now eager to adopt next-generation automated and scalable solutions with the shared goal to significantly increase market reach and broaden accessibility.Limula SA is a Life Science Tools company based in Lausanne, Switzerland, looking to disrupt the status quo in the manufacturing of Cell & Gene Therapies.